Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBQ6XY)

Drug Name

TP-3654 Drug Info

Synonyms

1361951-15-6; TP3654; UNII-EOB0N7BOY4; EOB0N7BOY4; SGI-9481; 2-((1r,4r)-4-((3-(3-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-6-yl)amino)cyclohexyl)propan-2-ol; SCHEMBL102560; CHEMBL3975308; SCHEMBL19986953; SCHEMBL20794171; SCHEMBL22421478; BDBM242374; BCP30070; EX-A1828; NSC805149; AKOS032960444; CS-6293; NSC-805149; SB17245; TP3654; TP 3654; BS-15262; HY-101126; AK00792306; S6774; US9416132, 8-31; 2-(4-((3-(3-(Trifluoromethyl)phenyl)imidazo(1,2-b)pyridazin-6-yl)amino)cyclohexyl)propan-2-ol; 4-((3-(3-(Trifluoromethyl)phenyl)imidazo(1,2-b)pyridazin-6-yl)amino) -trans-cyclohexyl)propan-2-ol

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

PubChem CID: 66598080
CAS Number: CAS 1361951-15-6
TTD Drug ID: DMBQ6XY

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Serine/threonine-protein kinase pim (PIM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SEL24	DMD37Q5	Acute myeloid leukaemia	2A60	Phase 1/2	[3]
INCB53914	DMKMSP2	Advanced malignancy	2A00-2F9Z	Phase 1/2	[4]
PIM447	DMU26OE	Myelofibrosis	2A20.2	Phase 1	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Serine/threonine-protein kinase pim (PIM)	TTA7WGU	NOUNIPROTAC	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03715504) Study of TP-3654 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.
3	A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia. Oncotarget. 2018 Mar 30;9(24):16917-16931.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)